Event: Recently, China’s mRNA vaccine has entered a period of accelerated progress. The mRNA vaccines of Shiyao and Cansino Biologics Inc(688185) have successively entered the clinical stage. At the same time, China Resources medicine has also accelerated the layout of mRNA vaccine technology.
On April 3, Shijiazhuang Pharmaceutical Group announced that its mRNA covid-19 vaccine sys6006 was approved for clinical use. Preclinical studies have shown that sys6006 has good immune protection against the current mainstream mutant strains including Omicron and delta. It can provide immune protection to the body through humoral immunity and cellular immunity, and produce memory B cells to provide long-term protection.
On April 4, Cansino Biologics Inc(688185) biology announced that its mRNA covid-19 vaccine was approved for clinical use. Preclinical research results show that the vaccine can induce high titer neutralizing antibodies against a variety of important variants identified by the World Health Organization (including the current epidemic strain). Compared with the existing covid-19 vaccine based on the prototype strain, it has a wider spectrum and can more effectively protect the body from the infection of the existing variants.
On April 7, Yunding Xinyao announced that it had signed a memorandum of cooperation with China Resources Pharmaceutical Group Co., Ltd. to establish an independent company focusing on the discovery, development and commercialization of mRNA vaccines. In addition, China Resources Pharmaceutical Group plans to make strategic equity investment in Yunding Xinyao mRNA technology platform.
Summary: at present, inspired by the great success of the commercialization of mRNA leading companies Moderna and biontech, many Chinese enterprises have invested in the mRNA track. On the domestic mRNA vaccine track, Walvax Biotechnology Co.Ltd(300142) – Aibo biology, s microorganism, Emmy vaccine, Haichang biology, Ruibo biology agna biology, Sinopharm Zhongsheng funuojian, ruikeji biology, weiszin biology, Cansino Biologics Inc(688185) , stone Pharmaceutical Group Blue Magpie biology and other enterprises are accelerating product research and development. MRNA domestic track is entering rapid development and ushering in huge growth.
Compared with traditional vaccines, mRNA vaccine has significant advantages: (1) safety advantages: mRNA can avoid the risk of genome integration, and mRNA expression efficiency is high, immunogenicity is high, and there is a natural metabolic degradation mechanism in the body; (2) Proprietary advantages: many proteins or intracellular proteins that are difficult to be proprietary can be encoded and expressed by mRNA, which can target targets that cannot be proprietary; (3) MRNA has a unique mechanism of action, which can trigger humoral and cellular immunity at the same time.
As a new technology, mRNA vaccine has played a great role in this epidemic, and its commercialization ability has been fully verified. In the future, with the accelerated rise of domestic mRNA vaccine companies, more relevant enterprises will enjoy the improvement of industry prosperity. Enterprises with core technologies in important links such as delivery technology will obtain good development opportunities. To sum up, continue to give the nucleic acid industry a “good” rating.
Risk warning: the sales of new products are less than expected; Risk of R & D; The risk of intensified industry competition; Macroeconomic downside risks.
